Salinomycin
(Sali) has selective toxicity to cancer stem cells
(CSCs), a subpopulation of cancer cells that have been recently linked
with tumor multidrug resistance (MDR). To utilize its selective toxicity
for cancer therapy, we sought to devise a nanoparticle (NP) carrier
to deliver Sali to solid tumors through the enhanced permeability
and retention effect and, hence, to increase its exposure to CSCs.
First, hydrophobic Sali was conjugated to a hydrophilic, immune-tolerant,
elastin-like polypeptide (iTEP); the amphiphilic iTEP–Sali
conjugates self-assemble into NPs. Next, free Sali was encapsulated
into the NPs alone or with two additives, N,N-dimethylhexylamine (DMHA) and α-tocopherol. The
coencapsulation significantly improved the loading efficiency and
release profile of Sali. The resulting NPs of the coencapsulation,
termed as iTEP–Sali NP3s, have an in vitro release half-life of 4.1 h, four times longer than iTEP–Sali
NP2s, the NPs that have encapsulated Sali only. Further, the NP3 formulation
increases the plasma area under curve and the tumor accumulation of
Sali by 10 and 2.4 times, respectively. Lastly, these improved pharmacokinetic
and tumor accumulation profiles are consistent with a boost of CSC-elimination
effect of Sali in vivo. In NP3-treated 4T1 orthotopic
tumors, the mean CSC frequency is 55.62%, a significant reduction
from the mean frequencies of untreated tumors, 75.00%, or free Sali-treated
tumors, 64.32%. The CSC-elimination effect of the NP3 can further
translate to a delay of tumor growth. Given the role of CSCs in driving
tumor MDR and recurrence, it could be a promising strategy to add
the NP3 to conventional cancer chemotherapies to prevent or reverse
the MDR.